ABAD: A potential therapeutic target for Aβ-induced mitochondrial dysfunction in Alzheimer's disease

Mini-Reviews in Medicinal Chemistry

Volumn 9, Issue 8, 2009, Pages 1002-1008

  Marques, A T ^a   Fernandes, P A ^a   Ramos, M J ^a  

^a UNIVERSITY OF PORTO   (Portugal)

Author keywords

ABAD; AG18051 inhibitor; Alzheimer's disease; Amyloid ; Frentizole; Mitochondrial dysfunction; Neuronal cell death; Oxidative stress

Indexed keywords

1 AZEPAN 1 YL 2 PHENYL 2 (4 THIOXO 1,4 DIHYDROPYRAZOLO[3,4 D]PYRIMIDIN 5 YL)ETHANONE; AG 18051; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN BINDING ALCOHOL DEHYDROGENASE; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; BETA SECRETASE; CASPASE 3; CYTOCHROME C; ENDOPHILIN; FRENTIZOLE; GAMMA SECRETASE; PEROXIREDOXIN 2; PROSTAGLANDIN SYNTHASE; PYRAZOLO[3,4 D]PYRIMIDINE DERIVATIVE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG TARGETING; GENE MUTATION; HUMAN; MITOCHONDRIAL MEMBRANE POTENTIAL; NERVE DEGENERATION; NONHUMAN; PATHOGENESIS; PROTEIN BINDING; PROTEIN CLEAVAGE; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEOMICS; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 70349090165     PISSN: 13895575     EISSN: None     Source Type: Journal    
DOI: 10.2174/138955709788681627     Document Type: Review

References (67)

1. Price, D.L.; Sisodia, S.S. Mutant genes in familial Alzheimer's disease and transgenic models. Annu. Rev. Neurosci., 1998, 21, 479-505.
2. Selkoe, D.J. Translating cell biology into therapeutic advances in Alzheimer's disease. Nature, 1999, 399, 23-31.
3. Reddy, P.H.; Mani, G.; Park, B.S.; Jacques, J.; Murdoch, G.; Whetsell, W.Jr.; Kaye, J.; Manczak, M. Differential loss of synaptic proteins in Alzheimer's disease: implications for synaptic dysfunction. J. Alzheimers Dis., 2005, 7, 103-17.
4. Golde, T.E. Inflammation takes on Alzheimer disease. Nat. Med., 2002, 8, 936-38.
5. Reddy, P.H.; McWeeney, S.; Park, B.S.; Manczak, M.; Gutala, R.V.; Partovi, D.; Jung, Y.; Yau, V.; Searles, R.; Mori, M.; Quinn, J. Gene expression profiles of transcripts in amyloid precursor protein transgenic mice: up-regulation of mitochondrial metabolism and apoptotic genes is an early cellular change in Alzheimer's disease. Hum. Mol. Genet., 2004, 13, 1225-40.
6. Reddy, P.H.; Beal, M.F. Are mitochondria critical in the pathogenesis of Alzheimer's disease? Brain Res. Rev., 2005, 49, 618-32.
7. Reddy, P.H.; McWeeney, S. Mapping cellular transcriptosomes in autopsied Alzheimer's disease subjects and relevant animal models. Neurobiol. Aging, 2006, 27, 1060-77.
8. Keller, J.N. Age-related neuropathology, cognitive decline, and Alzheimer's disease. Ageing Res. Rev., 2006, 5, 1-13.
9. Selkoe, D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev., 2001, 81, 741-66.
10. Hardy, J.A.; Higgins, G.A. Alzheimer's disease: the amyloid cascade hypothesis. Science, 1992, 256, 184-5.
11. Dahlgren, K.N.; Manelli, A.M.; Stine, W.B.Jr; Baker, L.K.; Krafft, G.A.; LaDu, M.J. Oligomeric and fibrillar species of amyloid-β peptides differentially affect neuronal viability. J. Biol. Chem., 2002, 277, 32046-53.
12. Gouras, G.K.; Tsai, J.; Naslund, J.; Vincent, B.; Edgar, M.; Checler, F.; Greenfield, J.P.; Haroutunian, V.; Buxbaum, J.D.; Xu, H.; Greengard, P.; Relkin, N.R. Intraneuronal Aβ42 accumulation in human brain. Am. J. Pathol., 2000, 156, 15-20.
13. Wirths, O.; Multhaup, G.; Bayer, T.A. A modified β-amyloid hypothesis: intraneuronal accumulation of the β-amyloid peptide - the first step of a fatal cascade. J. Neurochem., 2004, 91, 513-20.
14. Pereira, C.; Agostinho, P.; Moreira, P.I.; Cardoso, S.M.; Oliveira, C.R. Alzheimer's disease-associated neurotoxic mechanisms and neuroprotective strategies. Curr. Drug Targets CNS Neurol. Disord., 2005, 4, 383-403.
15. Hirai, K., Aliev, G.; Nunomura, A.; Fujioka, H.; Russell, R.L.; Atwood, C.S.; Johnson, A.B.; Kress, Y.; Vinters, H.V.; Tabaton, M.; Shimohama, S.; Cash, A.D.; Siedlak, S.L.; Harris, P.L.; Jones, P.K.; Petersen, R.B.; Perry, G.; Smith, M.A. Mitochondrial abnormalities in Alzheimer's disease. J. Neurosci., 2001, 21, 3017-23.
16. Duara, R.; Grady, C.; Haxby, J.; Sundaram, M.; Cutler, N.R.; Heston, L.; Moore, A.; Schlageter, N.; Larson, S.; Rapoport, S.I. Positron emission tomography in Alzheimer's disease. Neurology, 1986, 7, 879-87.
17. Bubber, P.; Haroutunian, V.; Fisch, G.; Blass, J.P.; Gibson, G.E. Mitochondrial abnormalities in Alzheimer brain: mechanistic implications. Ann. Neurol., 2005, 57, 695-703.
18. Parker, W.D.Jr.; Filley, C.M.; Parks, J.K. Cytochrome oxidase deficiency in Alzheimer's disease. Neurology, 1990, 40, 1302-03.
19. Butterfield, D.A.; Drake, J.; Pocernich, C.; Castegna, A. Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid β-peptide. Trends Mol. Med., 2001, 7, 548-54.
20. LaFerla, F.M. Calcium dyshomeostasis and intracellular signalling in Alzheimer's disease. Nat. Rev. Neurosci., 2002, 3, 862-72.
21. Manczak, M.; Park, B.S.; Jung, Y.; Reddy, P.H. Differential expression of oxidative phosphorylation genes in patients with Alzheimer's disease: implications for early mitochondrial dysfunction and oxidative damage. Neuromol. Med., 2004, 5, 147-62.
22. Fernandez-Vizarra, P.; Fernandez, A.P.; Castro-Blanco, S.; Serrano, J.; Bentura, M.L.; Martinez-Murillo, R.; Martinez, A.; Rodrigo, J. Intra- and extracellular Aβ and PHF in clinically evaluated cases of Alzheimer's disease. Histol. Histopathol., 2004, 19, 823- 44.
23. Lustbader, J.W.; Cirilli, M.; Lin, C.; Xu, H.W.; Takuma, K.; Wang, N.; Caspersen, C.; Chen, X.; Pollak, S.; Chaney, M.; Trinchese, F.; Liu, S.; Gunn-Moore, F.; Lue, L.F.; Walker, D.G.; Kuppusamy, P.; Zewier, Z.L.; Arancio, O.; Stern, D.; Yan, S.S.; Wu, H. ABAD directly links Aβ to mitochondrial toxicity in Alzheimer's disease. Science, 2004, 304, 448-52.
24. Kim, H.S.; Lee, J.H.; Lee, J.P.; Kim, E.M.; Chang, K.A.; Park, C.H.; Jeong, S.J.; Wittendorp, M.C.; Seo, J.H.; Choi, S.H.; Suh, Y.H. Aβ peptide induces cytochrome c release from isolated mitochondria. Neuroreport., 2002, 13, 1989-93.
25. 1-4'2. J. Neurosci., 2005, 25, 672-79.
26. Aleardi, A.M.; Benard, G.; Augereau, O.; Malgat, M.; Talbot, J.C.; Mazat, J.P.; Letellier, T.; Dachary-Prigent, J.; Solaini, G.C.; Rossignol, R. Gradual alteration of mitochondrial structure and function by β-amyloids: importance of membrane viscosity changes, energy deprivation, reactive oxygen species production, and cytochrome c release. J. Bioenerg. Biomembr., 2005, 37, 207-25.
27. Moreira, P.I.; Santos, M.S.; Moreno, A.; Rego, A.C.; Oliveira, C. Effect of amyloid β-peptide on permeability transition pore: A comparative study. J. Neurosci. Res., 2002, 69, 257-67.
28. Yan, S.D.; Fu, J.; Soto, C.; Chen, X.; Zhu, H.; Al-Mohanna, F.; Collison, K.; Zhu, A.; Stern, E.; Saido, T.; Tohyama, M.; Ogawa, S.; Roher, A.; Stern, D. An intracellular protein that binds amyloid-β peptide and mediates neurotoxicity in Alzheimer's disease. Nature, 1997, 389, 689-95.
29. Furuta, S.; Kobayashi, A.; Miyazawa, S.; Hashimoto, T. Cloning and expression of cDNA for newly identified isozyme of bovine liver 3-hydroxyacyl-CoA dehydrogenase and its import into mitochondria. Biochim. Biophys. Acta, 1997, 1350, 317-24
30. He, X.Y.; Schulz, H.; Yang, S.Y. A human brain L-3-hydroxyacyl coenzyme A dehydrogenase is identical to an amyloid β-peptidebinding protein involved in Alzheimer's disease. J. Biol. Chem., 1998, 273, 10741-46.
31. Powell, A.J.; Read, J.A.; Banfield, M.J.; Gunn-Moore, F.; Yan, S.D.; Lustbader, J.; Stern, A.R.; Stern, D.M.; Brady, R.L. Recognition of structurally diverse substrates by type II 3-hydroxyacyl-CoA dehydrogenase (HADH II)/amyloid-β binding alcohol dehydrogenase (ABAD). J. Mol. Biol., 2000, 303, 311-27.
32. Kissinger, C.R.; Rejto, P.A.; Pelletier, L.A.; Thomson, J.A.; Showalter, R.E.; Abreo, M.A.; Agree, C.S.; Margosiak, S.; Meng. J.J.; Aust, R.M.; Vanderpool. D.; Li, B.; Tempczyk-Russell, A.; Villafranca, J.E. Crystal structure of human ABAD/HSD10 with a bound inhibitor: implications for design of Alzheimer's disease therapeutics. J. Mol. Biol., 2004, 342, 943-52.
33. Yang, S.Y.; He, X.Y.; Schulz, H. Multiple functions of type 10 17β-hydroxysteroid dehydrogenase. Trends Endocrinol. Metab., 2005, 16, 167-75.
34. He, X.Y.; Wen, G.Y.; Merz, G.; Lin, D.; Yang, Y.Z.; Mehta, P.; Schulz, H.; Yang, S.Y. Abundant type 10 17β-hydroxysteroid dehydrogenase in the hippocampus of mouse Alzheimer's disease model. Mol. Brain Res., 2002, 90, 46-53.
35. Ofman, R.; Ruiter, J.; Feenstra, M.; Duran, M.; Toll-The, B.; Zschocke, J.; Ensenauer, R.; Lehnart, W.; Sass, J.; Sperl, W.; Wanders, R. 2-methyl-3-hydroxybutyryl-CoA dehydrogenase deficiency is caused by mutations in the HADH2 gene. Am. J. Hum. Genet., 2003, 72, 1300-07
36. Yan, S.D.; Zhu, Y.; Stern, E.D.; Hwang, Y.C.; Hori, O.; Ogawa, S.; Frosch, M.P.; Connolly, E.S.; McTaggert, R.; Pinsky, D.J.; Clarke, S.; Stern, D.M.; Ramasamy, R. Amyloid β-peptide-binding alcohol dehydrogenase is a component of the cellular response to nutritional stress. J. Biol. Chem., 2000, 275, 27100-09.
37. He, X.Y.; Yang, Y.Z.; Peehl, D.M.; Lauderdale, A.; Schulz, H.; Yang, S.Y. Oxidative 3α-hydroxysteroid dehydrogenase activity of human type 10 17β-hydroxysteroid dehydrogenase. J. Steroid Biochem. Mol. Biol., 2003, 87, 191-98.
38. Ivell, R.; Balvers, M.; Anand, R.J.; Paust, H.J.; Mckinnell, C.; Sharpe, R. Differentiation-dependent expression of 17β-hydroxysteroid dehydrogenase, type 10, in the rodent testis: effect of aging in Leydig cells. Endocrinology, 2003, 144, 3130-37.
39. He, X.Y.; Wegiel, J.; Yang, S.Y. Intracellular oxidation of allopregnanolone by human brain type 10 17β-hydroxysteroid dehydrogenase. Brain Res., 2005, 1040, 29-35.
40. He, X.Y.; Wegiel, J.; Yang, Y.Z.; Pullarkat, R.; Schulz, H.; Yang, S.Y. Type 10 17β-hydroxysteroid dehydrogenase catalyzing the oxidation of steroid modulators of γ-aminobutyric acid type A receptors. Mol. Cell. Endocrinol., 2005, 229, 111-17.
41. Majewska, M.D. Neurosteroids: endogenous bimodal modulators of the GABAA receptor. Mechanism of action and physiological significance. Prog. Neurobiol., 1992, 38, 379-95.
42. Laumonnier, F.; Cuthbert, P.C.; Grant, S.G. The role of neuronal complexes in human X-linked brain diseases. Am. J. Hum. Genet., 2007, 80, 205-20.
43. Siekevitz, P. The postsynaptic density: A possible role in longlasting effects in the central nervous system. Proc. Natl. Acad. Sci. USA, 1985, 82, 3494-98.
44. Lenski, C.; Kooy, R.F.; Reyniers, E.; Loessner, D.; Wanders, R.J.; Winnepenninckx, B.; Hellebrand, H.; Engert, S.; Schwartz, C.E.; Meindl, A.; Ramser, J. The reduced expression of the HADH2 protein causes X-linked mental retardation, choreoathetosis, and abnormal behavior. Am. J. Hum. Genet., 2007, 80, 372-77.
45. Perez-Cerda, C.; García-Villoria, J.; Ofman, R.; Sala, P.R.; Merinero, B.; Ramos, J.; García-Silva, M.T.; Beseler, B.; Dalmau, J.; Wanders, R.J.; Ugarte, M.; Ribes, A. 2-Methyl-3-Hydroxybutyryl-CoA Dehydrogenase (MHBD) Deficiency: An X-linked Inborn Error of Isoleucine Metabolism that May Mimic a Mitochondrial Disease. Pediatr. Res., 2005, 58, 488-91.
46. Zschocke, J.; Ruiter, J.P.; Brand, J.; Lindner, M.; Hoffmann, G.F.; Wanders, R.J., Mayatepek, E. Progressive infantile neurodegeneration caused by 2-methyl-3-hydroxybutyryl-CoA dehydrogenase deficiency: a novel inborn error of branched-chain fatty acid and isoleucine metabolism. Pediatr. Res., 2000, 48, 852-55.
47. Torroja, L.; Ortuño-Sahagún, D.; Ferrús, A.; Hämmerle, B.; Barbas, J.A. Scully, an essential gene of Drosophila, is homologous to mammalian mitochondrial type II L-3-hydroxyacyl-CoA dehydrogenase/amyloid-β peptide-binding protein. J. Cell Biol., 1998, 141, 1009-17.
48. Zhang, Y.; Wang, L.; Shao, M.; Li, J.; Li, B.; Zhang, H. A comparative study on the developmental expression of hadh2 in amphioxus and zebrafish. J. Fish Biol., 2008, 72, 1215-22.
49. Takuma, K.; Yao, J.; Huang, J.; Xu, H.; Chen, X.; Luddy, J.; Trillat, A.C.; Stern, D.M.; Arancio, O.; Yan, S.S. ABAD enhances Aβ-induced cell stress via mitochondrial dysfunction. FASEB J., 2005, 19, 597-8
50. Oppermann, U.C.T.; Salim, S.; Tjernberg, L.O.; Terenius, L.; Jörnvall, H. Binding of amyloid β-peptide to mitochondrial hydroxyacyl-CoA dehydrogenase (ERAB): regulation of an SDR enzyme activity with implications for apoptosis in Alzheimer's disease. FEBS Lett., 1999, 451, 238-42.
51. Yan, Y.; Liu, Y.; Sorci, M.; Belfort, G.; Lustbader, J.W.; Yan, S.S.; Wang, C. Surface plasmon resonance and nuclear magnetic resonance studies of ABAD-Aβ interaction. Biochemistry, 2007, 46, 1724-31.
52. Yan, S.D.; Stern, D.M. Mitochondrial dysfunction and Alzheimer's disease: role of amyloid-β peptide alcohol dehydrogenase (ABAD). Int. J. Exp. Pathol., 2005, 86, 161-71.
53. Ren, Y.; Xu, H.W.; Davey, F.; Taylor, M.; Aiton, J.; Coote, P.; Fang, F.; Yao, J.; Chen, D.; Chen, J.X.; Yan, S.D.; Gunn-Moore, F.J. Endophilin I expression is increased in the brains of Alzheimer disease patients. J. Biol. Chem., 2008, 283, 5685-91.
54. Yao, J.; Taylor, M.; Davey, F.; Ren, Y.; Aiton, J.; Coote, P.; Fang, F.; Chen, J.X.; Yan, S.D.; Gunn-Moore, F.J. Interaction of amyloid binding alcohol dehydrogenase/Aβ mediates up-regulation of peroxiredoxin II in the brains of Alzheimer's disease patients and a transgenic Alzheimer's disease mouse model. Mol. Cell Neurosci., 2007, 35, 377-82.
55. Manczak, M.; Anekonda, T.S.; Henson, E.; Park, B.S.; Quinn, J.; Reddy, P.H. Mitochondria are a direct site of Aβ accumulation in Alzheimer's disease neurons: implications for free radical generation and oxidative damage in disease progression. Hum. Mol. Genet., 2006, 15, 1437-49
56. Reutens, A.T.; Begley, C.G. Endophilin-1: a multifunctional protein. Int. J. Biochem. Cell Biol., 2002, 34, 1173-77.
57. Ramjaun, A.R.; Angers, A.; Legendre-Guillemin, V.; Tong, X.K.; McPherson, P.S. Endophilin regulates JNK activation through its interaction with the germinal center kinase-like kinase. J. Biol. Chem., 2001, 276, 28913-19.
58. Borsello, T.; Forloni, G. JNK signalling: a possible target to prevent neurodegeneration. Curr. Pharm. Des., 2007, 13, 1875-86.
59. Bozyczko-Coyne, D.; O'Kane, T.M.; Wu, Z.L.; Dobrzanski, P.; Murthy, S.; Vaught, J.L.; Scott, R.W. CEP-1347/KT-7515, an inhibitor of SAPK/JNK pathway activation, promotes survival and blocks multiple events associated with Aβ-induced cortical neuron apoptosis. J. Neurochem., 2001, 77, 849-63.
60. Minogue, A.M.; Schmid, A.W.; Fogarty, M.P.; Moore, A.C.; Campbell, V.A.; Herron, C.E.; Lynch, M.A. Activation of the JNK signalling cascade mediates the effect of Aβ on LTP and cell death in hippocampus: a role for IL-1β. J. Biol. Chem., 2003, 278, 27971-80.
61. Morishima, Y.; Gotoh, Y.; Zieg, J.; Barrett, T.; Takano, H.; Flavell, R.; Davis, R.J.; Shirasaki, Y.; Greenberg, M.E. β-amyloid induces neuronal apoptosis via a mechanism that involves the c-Jun Nterminal kinase pathway and the induction of Fas ligand. J. Neurosci., 2001, 21, 7551-60.
62. Troy, C.M.; Rabacchi, S.A.; Xu, Z.; Maroney, A.C.; Connors, T.J.; Shelanski, M.L.; Greene, L.A. β-Amyloid-induced neuronal apoptosis requires c-Jun N-terminal kinase activation. J. Neurochem., 2001, 77, 157-64.
63. Wei, W.; Wang, X.; Kusiak, J.W. Signaling events in amyloid β-peptide-induced neuronal death and IGF-I protection. J. Biol. Chem., 2002, 277, 17649-56.
64. Kim, S.H.; Fountoulakis, M.; Cairns, N.; Lubec, G. Protein levels of human peroxiredoxin subtypes in brains of patients with Alzheimer's disease and Down syndrome. J. Neural Transm. Suppl., 2001, 61, 223-35.
65. Krapfenbauer, K.; Engidawork, E.; Cairns, N.; Fountoulakis, M.; Lubec, G.; A berrant expression of peroxiredoxin subtypes in neurodegenerative disorders. Brain Res., 2003, 967, 152-60.
66. Wood, Z.A.; Schröder, E.; Robin Harris, J.; Poole, L.B. Structure, mechanism and regulation of peroxiredoxins. Trends Biochem. Sci., 2003, 28, 32-40.
67. Xie, Y.; Deng, S.; Chen, Z.; Yan, S.; Landry, D.W. Identification of small-molecule inhibitors of the Abeta-ABAD interaction. Bioorg. Med. Chem. Lett., 2006, 16, 4657-60.